|
1
|
Du Bois A, Lück HJ, Meier W, et al:
Carboplatin plus paclitaxel as first-line chemotherapy in
previously untreated advanced ovarian cancer. German AGO Study
Group Ovarian Cancer. Arbeitsgemeinschaft Gynäkologische Onkologie.
Semin Oncol. 24(4 Suppl 11): S11-28–S11-33. 1997.PubMed/NCBI
|
|
2
|
Aravantinos G, Fountzilas G, Kosmidis P,
et al: Paclitaxel plus carboplatin versus paclitaxel plus
alternating carboplatin and cisplatin for initial treatment of
advanced ovarian cancer: long-term efficacy results: a Hellenic
Cooperative Oncology Group (HeCOG) study. Ann Oncol. 16:1116–1122.
2005. View Article : Google Scholar
|
|
3
|
Buttmann M, Nowak E, Kroner A, Hemmer B,
Lesch KP and Rieckmann P: Analysis of the stathmin rs182455 single
nucleotide promoter polymorphism in patients with multiple
sclerosis. J Neurogenet. 22:181–186. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lippert TH, Ruoff H and Volm M: Intrinsic
and Acquired Drug Resistance in Malignant Tumors. The main reason
for therapeutic failure. Arzneimittelforschung. 58:261–264.
2008.PubMed/NCBI
|
|
5
|
Fleming ND, Agadjanian H, Nassanian H, et
al: Xeroderma pigmentosum complementation group C single-nucleotide
polymorphisms in the nucleotide excision repair pathway correlate
with prolonged progression-free survival in advanced ovarian
cancer. Cancer. 118:689–697. 2012. View Article : Google Scholar
|
|
6
|
Lose F, Nagle CM, O’Mara T, et al:
Vascular endothelial growth factor gene polymorphisms and ovarian
cancer survival. Gynecol Oncol. 119:479–483. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Quaye L, Gayther SA, Ramus SJ, et al: The
effects of common genetic variants in oncogenes on ovarian cancer
survival. Clin Cancer Res. 14:5833–5839. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Belmont LD and Mitchison TJ:
Identification of a protein that interacts with tubulin dimers and
increases the catastrophe rate of microtubules. Cell. 84:623–631.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Golouh R, Cufer T, Sadikov A, et al: The
prognostic value of Stathmin-1, S100A2, and SYK proteins in
ER-positive primary breast cancer patients treated with adjuvant
tamoxifen mono-therapy: an immunohistochemical study. Breast Cancer
Res Treat. 110:317–326. 2008. View Article : Google Scholar
|
|
10
|
Zheng P, Liu YX, Chen L, et al: Stathmin,
a new target of PRL-3 identified by proteomic methods, plays a key
role in progression and metastasis of colorectal cancer. J Proteome
Res. 9:4897–4905. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Trovik J, Wik E, Stefansson IM, et al:
Stathmin overexpression identifies high-risk patients and lymph
node metastasis in endometrial cancer. Clin Cancer Res.
17:3368–3377. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Canzonieri V, Barzan L, Franchin G, et al:
Alteration of G1/S transition regulators influences recurrences in
head and neck squamous carcinomas. J Cell Physiol. 227:233–238.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Singer S, Ehemann V, Brauckhoff A, et al:
Protumorigenic over-expression of stathmin/Op18 by gain-of-function
mutation in p53 in human hepatocarcinogenesis. Hepatology.
46:759–768. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rosell R, Scagliotti G, Danenberg KD, et
al: Transcripts in pretreatment biopsies from a three-arm
randomized trial in metastatic non-small-cell lung cancer.
Oncogene. 22:3548–3553. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wei SH, Lin F, Wang X, Gao P and Zhang HZ:
Prognostic significance of stathmin expression in correlation with
metastasis and clinicopathological characteristics in human ovarian
carcinoma. Acta Histochem. 110:59–65. 2008. View Article : Google Scholar
|
|
16
|
Ghosh R, Gu G, Tillman E, et al: Increased
expression and differential phosphorylation of stathmin may promote
prostate cancer progression. Prostate. 67:1038–1052. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Carr JR, Park HJ, Wang Z, Kiefer MM and
Raychaudhuri P: FoxM1 mediates resistance to herceptin and
paclitaxel. Cancer Res. 70:5054–5063. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Alli E, Yang JM and Hait WN: Silencing of
stathmin induces tumor-suppressor function in breast cancer cell
lines harboring mutant p53. Oncogene. 26:1003–1012. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Su D, Smith SM, Preti M, et al: Stathmin
and tubulin expression and survival of ovarian cancer patients
receiving platinum treatment with and without paclitaxel. Cancer.
115:2453–2463. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shepherd JH: Revised FIGO staging for
gynaecological cancer. Br J Obstet Gynaecol. 96:889–892. 1989.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Scully RE and Sobin LH: Histologic typing
of ovarian tumors. Arch Pathol Lab Med. 111:794–795.
1987.PubMed/NCBI
|
|
22
|
Miller AB, Hoogstraten B, Staquet M and
Winkler A: Reporting results of cancer treatment. Cancer.
47:207–214. 1981. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rustin GJ, Nelstrop AE, Tuxen MK and
Lambert HE: Defining progression of ovarian carcinoma during
follow-up according to CA 125: a North Thames Ovary Group Study.
Ann Oncol. 7:361–364. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sobel A and Tashjian AH Jr: Distinct
patterns of cytoplasmic protein phosphorylation related to
regulation of synthesis and release of prolactin by GH cells. J
Biol Chem. 258:10312–10324. 1983.PubMed/NCBI
|
|
25
|
Belletti B and Baldassarre G: Stathmin: a
protein with many tasks. New biomarker and potential target in
cancer. Expert Opin Ther Target. 15:1249–1266. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Saunders MA, Liang H and Li WH: Human
polymorphism at microRNAs and microRNA target sites. Proc Natl Acad
Sci USA. 104:3300–3305. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sun G, Yan J, Noltner K, et al: SNPs in
human miRNA genes affect biogenesis and function. RNA.
15:1640–1651. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Pagani F and Baralle FE: Genomic variants
in exons and introns: identifying the splicing spoilers. Nat Rev
Genet. 5:389–396. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jourdain I, Lachkar S, Charbaut E, et al:
A synergistic relationship between three regions of stathmin family
proteins is required for the formation of a stable complex with
tubulin. Biochem J. 378:877–888. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Jourdain L, Curmi P, Sobel A, Pantaloni D
and Carlier MF: Stathmin: a tubulin-sequestering protein which
forms a ternary T2S complex with two tubulin molecules.
Biochemistry. 36:10817–10821. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Oishi Y, Nagasaki K, Miyata S, et al:
Functional pathway characterized by gene expression analysis of
supraclavicular lymph node metastasis-positive breast cancer. J Hum
Genet. 52:271–279. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Salvesen HB, Carter SL, Mannelqvist M, et
al: Integrated genomic profiling of endometrial carcinoma
associates aggressive tumors with indicators of PI3 kinase
activation. Proc Natl Acad Sci USA. 106:4834–4839. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yuan RH, Jeng YM, Chen HL, et al: Stathmin
overexpression cooperates with p53 mutation and osteopontin
overexpression, and is associated with tumour progression, early
recurrence, and poor prognosis in hepatocellular carcinoma. J
Pathol. 209:549–558. 2006. View Article : Google Scholar
|
|
34
|
Meng XL, Su D, Wang L, et al: Low
expression of stathmin in tumor predicts high response to
neoadjuvant chemotherapy with docetaxel-containing regimens in
locally advanced breast cancer. Genet Test Mol Biomarkers.
16:689–694. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Brocke B, Lesch KP, Armbruster D, et al:
Stathmin, a gene regulating neural plasticity, affects fear and
anxiety processing in humans. Am J Med Genet B Neuropsychiatr
Genet. 153B:243–251. 2010.PubMed/NCBI
|
|
36
|
Ehlis AC, Bauernschmitt K, Dresler T, et
al: Influence of a genetic variant of the neuronal growth
associated protein Stathmin 1 on cognitive and affective control
processes: an event-related potential study. Am J Med Genet B
Neuropsychiatr Genet. 156B:291–302. 2011. View Article : Google Scholar
|
|
37
|
Yamada K, Matsuzaki S, Hattori T, et al:
Increased stathmin1 expression in the dentate gyrus of mice causes
abnormal axonal arborizations. PLoS One. 5:e85962010. View Article : Google Scholar : PubMed/NCBI
|
